MCAF, Recombinant, Human (MCP-1, Macrophage/Monocyte Chemotactic and Activating Factor)

Recombinant Human MCP-1 also known as Monocyte Chemotactic and Activating Factor (MCAF) is a non-glycosylated, Polypeptide chain containing 76 amino acids and having a molecular mass of 8607 Dalton.\n\nSequence:\nThe sequence of the first five N-terminal amino acids was determined and was found to be Gln-Pro-Asp-Ala-Ile.\n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity:\nMCP-1 is fully biologically active when compared to standard. The specific activity as determined by the ability of MCP-1 to chemoattract human Monocytes using a concentration of 5-20ng/ml.\n\nEndotoxin:\n(same/less than) 0.1ng/ug (IEU/ug) of rHuMCP-1.\n\nProtein Content:\nProtein quantitation was carried out by two independent methods:\n1. UV spectroscopy at 280nm. \n2. Analysis by RP-HPLC, using a standard solution of MCP-1 as a Reference Standard.\n\nReconstitution:\nReconstitute the lyophilized rHuMCP-1 in sterile 18MOmega-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.\n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M2690-01

Size

5ug

Form

Supplied as a lyophilized powder. No additives.

Purity

(same/more than) 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.

References

1. Differential effects of MCP-1 and leptin on collateral flow and arteriogenesis. Schirmer SH, Buschmann IR, Hoefer IE, Bode C, Cardiovasc Res 2004 Nov 1;64(2):356-64 2. Negative association between circulating total homocysteine and proinflammatory chemokines MCP-1 and RANTES in prepubertal lean, but not in obese, children. Economou EV, Malamitsi-Puchner AV, Kouskouni EE, Creatsas G, J Cardiovasc Pharmacol 2004 Sep;44(3):310-5 3. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Fenoglio C, Galimberti D, Guidi I, Mariani C, Neurobiol Aging 2004 Oct;25(9):1169-73 4. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer's disease in Italians. Pola R, Flex A, Proia AS, Pecorini G, Exp Gerontol 2004 Aug;39(8):1249-52 5. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Chang L, Ernst T, Conant K, Antivir Ther 2004 Jun;9(3):431-40 6. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. Hiraoka M, Nitta N, Shimokado K, Life Sci 2004 Jul 30;75(11):1333-41.